Under construction – not a live service
Sign in

2023-510544-21-00RecruitingPhase 1

INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study.

Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Jun 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
4 (estimated)
First submitted
2 Jul 2024
Start date
18 Feb 2025
Lead sponsor
UZ Leuven
Diseases
Melanoma
EU CT number
2023-510544-21-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 4
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced malignant melanoma who receive anti-PD1 therapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced malignant melanoma.
Earlier treatment
People receive anti-PD1 therapy.

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
UZ LeuvenLeuvenBelgiumRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.